Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.990
-0.100 (-1.96%)
Aug 6, 2026, 11:19 AM EDT - Market open
Vanda Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, Vanda Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $13.69. The average 1-year stock price forecast is 174.35% higher than the current stock price, while the lowest is $5.75 (+15.23%) and the highest is $21 (+320.84%).
Price Target: $13.69 (+174.35%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vanda Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Buy Maintains $17 | Buy | Maintains | $17 | +240.68% | Jul 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $21 | Buy | Reiterates | $21 | +320.84% | Jul 9, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $18 | Buy | Maintains | $18 | +260.72% | May 7, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $11 | Buy | Maintains | $11 | +120.44% | Feb 23, 2026 |
Financial Forecast
Revenue This Year
262.10M
from 216.11M
Increased by 21.29%
Revenue Next Year
356.50M
from 262.10M
Increased by 36.01%
EPS This Year
0.96
EPS Next Year
1.04
from 0.96
Increased by 8.33%
EPS and Forward PE are based on non-GAAP adjusted numbers.